Cargando…

High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone

Detalles Bibliográficos
Autores principales:	Goto, Masahiro, Miyagawa, Naoyuki, Kikunaga, Kaori, Miura, Masaru, Hasegawa, Yukihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428773/ http://dx.doi.org/10.1186/1687-9856-2015-S1-P39

Ejemplares similares

Single serum cortisol values at 09:00 h can be indices of adrenocortical function in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone
por: Goto, Masahiro, et al.
Publicado: (2015)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
por: Van Anh, Khanh-Van Y., et al.
Publicado: (2020)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Impact of Early Treatment With High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children
por: Karimi Yazdi, Alireza, et al.
Publicado: (2021)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
por: Lee, Taek Jin, et al.
Publicado: (2008)

Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Chen, Chih-Jen, et al.
Publicado: (2012)

Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease
por: Xie, Tian, et al.
Publicado: (2017)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

FCN1 (M-ficolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease
por: Okuzaki, Daisuke, et al.
Publicado: (2017)

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Kim, Hyun Kwon, et al.
Publicado: (2011)

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease
por: Kemmotsu, Yasushi, et al.
Publicado: (2011)

Peripheric arterial aneurisyms and monocytosis in intravenous immunoglobulin treatment resistant Kawasaki disease
por: Baskin, E, et al.
Publicado: (2008)

Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease
por: Lee, Hye Young, et al.
Publicado: (2016)

Thrombospondin-2 predicts response to treatment with intravenous immunoglobulin in children with Kawasaki disease
por: Yang, Shuai, et al.
Publicado: (2018)

Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease
por: Jun, Jae Sung, et al.
Publicado: (2017)

White Blood Cell and Neutrophil Counts and Response to Intravenous Immunoglobulin in Kawasaki Disease
por: Muto, Taichiro, et al.
Publicado: (2019)

Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data
por: Lam, Jonathan Y., et al.
Publicado: (2023)

Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease
por: Ueno, Kentaro, et al.
Publicado: (2021)

Optimising prednisolone or prednisone replacement in adrenal insufficiency
por: Sharma, Angelica, et al.
Publicado: (2023)

Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial
por: Lin, Si-Yuan, et al.
Publicado: (2021)

Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease
por: Yeo, Joong-Seok, et al.
Publicado: (2010)

Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study
por: Lin, Ming-Chih, et al.
Publicado: (2013)

Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease
por: Ou-Yang, Mei-Chen, et al.
Publicado: (2013)

Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease
por: Baek, Jin-Young, et al.
Publicado: (2016)

A comparison of efficacy of six prediction models for intravenous immunoglobulin resistance in Kawasaki disease
por: Qian, Weiguo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p6nk8r3i637avitdje4rinf9ko